Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and Abemaciclib in ER+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor Failure
NCT05305924Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2−), sponsored by Houston Methodist Research Institute. Primary endpoint: Time to Treatment Failure. Started Feb 2021; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2−)
Beyond the preview
Go deeper on NCT05305924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05305924.